基因治疗作为 HIV-1 的疫苗。

Gene therapy as a vaccine for HIV-1.

机构信息

University of Amsterdam, Center for Infection and Immunity Amsterdam, Academic Medical Center, Department of Medical Microbiology, Laboratory of Experimental Virology, Meibergdreef 15, K3-110, 1105 AZ Amsterdam, The Netherlands.

出版信息

Expert Opin Biol Ther. 2012 Oct;12(10):1315-21. doi: 10.1517/14712598.2012.707177. Epub 2012 Jul 18.

DOI:10.1517/14712598.2012.707177

PMID:22803517

Abstract

INTRODUCTION

An effective vaccine that can protect people against infection of the human immunodeficiency virus type 1 (HIV-1) remains elusive. HIV-1 vaccine research has encountered several false starts and a few causes for hope over the last 28 years, but no real success stories. Thus, it is time to think out of the box and design and test unorthodox vaccination strategies.

AREAS COVERED

Recent studies in mice and monkeys have revealed the potential of a gene therapy that provides vaccine-like protection against HIV-1 infection by producing a potent vector-encoded antibody that neutralizes the invading viruses. This novel strategy is called Vectored Immuno Prophylaxis or VIP, and it circumvents the sometimes difficult phases of regular vaccination protocols, that is, antigen design and induction of protective immune responses.

EXPERT OPINION

VIP is a prolonged form of passive immunization by means of a gene therapy. We will discuss the ins and outs of VIP and the therapeutic possibilities and challenges.

摘要

简介

一种能够有效预防人体感染人类免疫缺陷病毒 1 型（HIV-1）的疫苗仍未问世。在过去的 28 年中，HIV-1 疫苗的研究历经多次挫折，也出现了一些令人燃起希望的迹象，但都没有取得真正的成功。因此，是时候跳出固有思维，设计并测试非传统的疫苗接种策略了。

涵盖领域

最近在小鼠和猴子身上的研究表明，一种基因疗法具有提供 HIV-1 感染疫苗样保护的潜力，其通过产生一种强效的载体编码抗体来中和入侵的病毒。这种新策略被称为载体免疫预防（Vectored Immuno Prophylaxis 或 VIP），它规避了常规疫苗接种方案有时会遇到的困难阶段，即抗原设计和诱导保护性免疫反应。